Amer M. Zeidan

机构：Yale Cancer Center, Yale University · ORCID：0000-0001-7017-8160

发表论文 901 篇 · 总被引 13003 次 · h-index 57

代表论文

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database (2026 · Blood Cancer Journal · 被引 2)
Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS) (2026 · American Journal of Hematology)
The PRIME trial: An investigator‐initiated, multicentre, phase II study of the poly(ADP‐ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase ( IDH )‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes (2026 · British Journal of Haematology)
EXABS-120-MDS: Stalled Progress in Higher-Risk MDS: Can We Find an Off-Ramp? (2026 · Clinical Lymphoma Myeloma & Leukemia)
Supplementary Figure 6 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants (2026)
Supplementary Figure 8 from Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants (2026)